Altimmune, Inc. Common Stock
Here’s whether Altimmune, Inc. Common Stock (ALT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.37% over 10 days); RSI 49 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -20.1%. Currently 54.4% off its 52-week high. Score: +0/7.
ALT is trading below its 200-day MA ($3.72) — a key warning sign the longer-term trend is under pressure. An RSI of 48.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -20.1% compares to +20.4% for SPY (trailed the market by 40.5%). The current 54.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.